MILESTONE SCIENTIFIC INC. (MLSS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 35.17K USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 1.03M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -4.10M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $35.17K | (m) | $1.03M | $-4.10M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $878.61K | $-4.53M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $449.47K | (m) | $952.72K | $-5.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $654.67K | (m) | $1.19M | $-6.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $870.50K | (m) | $1.31M | $-6.99M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.13M | (m) | $1.36M | $-7.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $858.77K | (m) | $1.35M | $-6.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $818.14K | (m) | $1.36M | $-6.69M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $756.56K | (m) | $1.20M | $-6.73M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $655.24K | (m) | $1.39M | $-7.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $701.38K | (m) | $1.47M | $-7.11M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $777.46K | (m) | $1.51M | $-7.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $773.18K | (m) | $1.59M | $-7.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $826.09K | (m) | $1.58M | $-8.26M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.15M | (m) | $1.50M | $-8.83M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $1.19M | (m) | $1.39M | $-8.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $1.38M | (m) | $1.18M | $-8.32M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $1.33M | (m) | $982.78K | $-8.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $878.21K | (m) | $790.91K | $-7.38M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $658.80K | (m) | $973.01K | $-7.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $127.96K | (m) | $799.46K | $-6.53M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $216.81K | (m) | $633.14K | $-6.83M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $307.85K | (m) | $550.35K | $-7.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $317.20K | (m) | $113.65K | $-7.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $303.70K | (m) | $140.41K | $-6.85M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $291.06K | (m) | $157.62K | $-4.79M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $189.92K | (m) | $183.89K | $-4.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $139.80K | (m) | $308.44K | $-2.90M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $111.92K | (m) | $339.82K | $-6.50M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $26.16K | (m) | $379.20K | $-6.82M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $245.64K | (m) | $409.02K | $-8.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $246.44K | (m) | $367.87K | $-9.72M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $283.26K | (m) | $584.46K | $-6.58M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $393.55K | (m) | $621.50K | $-6.71M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $272.75K | (m) | $651.41K | $-5.23M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $756.39K | (m) | (m) | $-5.32M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $1.04M | (m) | (m) | $-5.53M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.23M | (m) | (m) | $-6.10M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.27M | (m) | (m) | $-6.51M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $807.28K | (m) | (m) | $-5.42M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $524.70K | (m) | (m) | $-4.64M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $234.18K | (m) | (m) | $-3.93M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $100.86K | (m) | (m) | $-3.06M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $63.60K | (m) | (m) | $-3.32M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $72.30K | (m) | (m) | $-2.65M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $82.64K | (m) | (m) | $-1.19M | $4.35K | (m) | (m) | -273.50× | Reported |
| 2014-12-31 | $88.24K | (m) | (m) | $-790.18K | $2.67K | (m) | (m) | -296.17× | Reported |
| 2014-09-30 | $88.18K | (m) | (m) | $924.33K | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $71.51K | (m) | (m) | $1.52M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $85.23K | (m) | (m) | $1.25M | $36.72K | (m) | (m) | 33.99× | Reported |
| 2013-12-31 | $191.34K | (m) | (m) | $1.09M | $70.80K | (m) | (m) | 15.35× | Reported |
| 2013-09-30 | $220.22K | (m) | (m) | $469.90K | $103.89K | (m) | (m) | 4.52× | Reported |
| 2013-06-30 | $267.89K | (m) | (m) | $85.28K | $134.75K | (m) | (m) | 0.63× | Reported |
| 2013-03-31 | $264.50K | (m) | (m) | $-119.44K | $168.06K | (m) | (m) | -0.71× | Reported |
| 2012-12-31 | $181.98K | (m) | (m) | $-520.35K | $175.91K | (m) | (m) | -2.96× | Reported |
| 2012-09-30 | $186.69K | (m) | (m) | $-535.13K | $184.38K | (m) | (m) | -2.90× | Reported |
| 2012-06-30 | $118.92K | (m) | (m) | $-1.13M | $183.50K | (m) | (m) | -6.14× | Reported |
| 2012-03-31 | $135.65K | (m) | (m) | $-1.34M | $154.87K | (m) | (m) | -8.62× | Reported |
| 2011-12-31 | $140.05K | (m) | (m) | $-1.22M | $131.84K | (m) | (m) | -9.28× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $270.49K | (m) | (m) | $-700.84K | $95.14K | (m) | (m) | -7.37× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifeward Ltd. (LFWD) | $0.021B | ||
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| ENvue Medical, Inc. (FEED) | United States | $0.011B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| LogicMark, Inc. (LGMK) | United States | $0.000B | |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |